Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Optimised Use of Romozosumab Study
NCT06059222Phase 4Recruiting
- Sponsor
- Aarhus University
- Start
- Oct 2023
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of romosozumab in osteoporosis (3 arms), sponsored by Aarhus University. Primary endpoint: Change in total hip Bone Mineral Density at 24 months. Started Oct 2023; status: recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06059222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059222.